Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

被引：0
|
作者：
Mariano A. Giorgi
Carlos P. Boissonnet
Paula Soledad Luque
Jimena Piastrella
Carlos Porley
Fernanda Ditata
Sergio Volman
机构：
[1] Instituto Universitario CEMIC (IUC),Health Economics and Technology Assessment Unit. Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC)
[2] Norberto Quirno” (CEMIC),Cardiology Section. Department of Internal Medicine. Centro de Educación Médica e Investigaciones Clínicas
[3] Instituto Universitario CEMIC (IUC),Associate Professor of Pharmacology
[4] Novartis Pharmaceutilcals,undefined
[5] Piastrella Worked at Novartis at the Time This Research Was Conducted,undefined
来源：
Health Economics Review | / 13卷
关键词：
Cost-effectiveness; Heart failure; Discount rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [2] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [3] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    HEART, 2018, 104 (12) : 1006 - 1013
  • [4] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [5] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [6] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION IN ITALY
    Mantovani, L. G.
    Cortesi, P. A.
    Senni, M.
    Deschaseaux, C.
    Haroun, R.
    Pitotti, C.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A650
  • [7] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [8] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [9] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [10] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
12345